报价延迟最少15分钟:2026/04/15 09:43 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.167 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.26/-3.89
|
|
企业价值
29.73M
|
| 资产负债 |
|
每股账面净值
2.23
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
20.97M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3. |
